ARCHIMED Acquires Groupe Laboratoire Rivadis

ARCHIMED Acquires Irrimax Corporation

August 28, 2024

Medical Devices

ARCHIMED, a healthcare-focused private equity firm, has acquired Irrimax Corporation, the Lawrenceville, Georgia-based developer of the Irrisept antimicrobial wound lavage system, through its MED Platform II fund. The partnership aims to scale Irrimax's product range, expand its market presence and accelerate global commercial reach; financial terms were not disclosed.

ARCHIMED and CDPQ Recapitalize Corealis Pharma

May 24, 2022

Pharmaceuticals

Transatlantic PE firm ARCHIMED, joined by Caisse de dépôt et placement du Québec (CDPQ), has recapitalized Corealis Pharma, a Laval, Quebec–based CDMO specializing in oral solid dosage formulation and clinical-supply manufacturing. The recapitalization will fund expansion of GMP-compliant facilities, R&D capabilities and accelerate growth for Corealis to serve small- and mid-sized biotech and pharma customers.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ARCHIMED Acquires WiQo S.p.A.

March 9, 2023

Medical Devices

ARCHIMED, a Europe-based healthcare private equity firm, has acquired WiQo, an Italian developer and manufacturer of the PRX‑T33 topical biostimulator used in aesthetic medicine. Founders (Dr. Rossana Castellana and family) retained a 25% stake and Castellana will stay on to lead R&D; the deal was financed with debt provided by Banco BPM and Crédit Agricole Italia and is the fourth investment from ARCHIMED's MED III fund.

ARCHIMED Acquires Majority Stake in Cardioline

November 17, 2021

Medical Devices

Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.